FDA clears next-gen BioFire FilmArray GI panels
Nov. 10, 2026—BioMérieux’s BioFire FilmArray Gastrointestinal 1.1 Panel has obtained FDA 510(k) clearance and IVDR CE marking, and its Gastrointestinal 1.1 Panel Mid also received 510(k) clearance.
Webinars and Commercial Conversations — Register Now
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Illumina products, presentations, meet and greets, and more at AMP ’26
As a trusted partner in precision oncology research, drop by Illumina booth No. 727 at AMP 2026 to discover how we’re helping laboratories advance today while preparing for the future of genomic research.
EntroGen highlights MGMT methylation testing at AMP 2026
Find out why laboratories are changing their MGMT methylation detection testing from pyrosequencing to qPCR with EntroGen kits.
Roche launches mesothelioma diagnostic test
Nov. 9, 2027—Roche has launched the Ventana BAP1 (SP527) Rabbit Monoclonal Primary Antibody.
Oxford Nanopore hosts oncology, rare disease workshops at AMP ’26
Oxford Nanopore will host two sponsored workshops on Nov. 11 at AMP 2026.
Agilent completes acquisition of Proscia
Nov. 6, 2026—Agilent Technologies has completed its acquisition of Proscia for $240 million in cash at closing, with up to an additional $30 million contingent on future performance milestones.
Bio-Techne Diagnostics presents corporate workshop at AMP 2026
Bio-Techne Diagnostics is presenting a corporate workshop at AMP 2026 titled “Deep Sensitivity Meets Workflow Efficiency: Optimizing HemOnc MRD Testing in Your Laboratory” on Wednesday, Nov. 11, 11–11:50 am, Chelan 2, Level 2/Arch at 800 Pike, Seattle Convention Center.
Siemens Healthineers unveils Olyrian Diagnostics as carve-out begins
Nov. 5, 2026—Siemens Healthineers has begun carving out its in vitro diagnostics business, with plans to launch it as a standalone company called Olyrian Diagnostics.
FDA clears Beckman Coulter Access MeMed BV assay
Nov. 4, 2026—The Food and Drug Administration has cleared Beckman Coulter Diagnostics’ Access MeMed BV assay.
Roche receives FDA 510(k) clearance for Cobas Eplex RP3
Nov. 3, 2026—The Roche Cobas Eplex respiratory pathogen panel 3 has received FDA 510(k) clearance, expanding the existing capabilities of the Cobas Eplex RP2 (EUA).